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MicroAbstract:  
Activation of Wnt/β-catenin signaling pathway is associated with malignant transformation, 
development of fibrosis and angiogenesis. We analyzed β-catenin mRNA expression in bone marrows 
of 29 patients with primary (PMF), four with secondary myelofibrosis (SMF) and 16 controls using 
qRT-PCR. Β-catenin expression is increased in both PMF and SMF and might potentiate anemia.  
 
Abstract:  
Introduction: Β-catenin is a central effector molecule of canonical Wnt signaling pathway. It is 
important for maintenance of stem cell homeostasis and its aberrant activation has been implicated in a 
wide array of malignant hematological disorders. There are few reports suggesting its dysregulation in 
Philadephia chromosome negative myeloproliferative neoplasms (Ph- MPNs). 
Patients and methods: We analyzed β-catenin mRNA expression in bone marrow (BM) aspirates of 29 
patients with primary (PMF) and four patients with secondary, post Ph- MPN, myelofibrosis (SMF) 
using qRT-PCR. Control group consisted of 16 BM aspirates from patients with limited-stage 
aggressive Non-Hodgkin lymphoma without BM involvement. We compared relative gene expression 
with clinical and hematological parameters. 
Results: Β-catenin relative expression differed significantly among groups (p=0.0002), it was 
significantly higher in patients with both PMF and SMF than in control group, but did not differ 
between PMF and SMF patients. Negative correlation was found regarding hemoglobin level in PMF 
(p=0,017). No association according to JAK2 V617F mutational status or JAK2 V617F allele burden 
was detected.  
Conclusion: Present study shows for the first time that β-catenin mRNA expression is increased in 
patients with both PMF and SMF and its upregulation might potentiate anemia. Number of 
inflammatory cytokines associated with PMF are capable of mediating their effects through increased 
β-catenin expression. Accordingly, β-catenin can induce expression of number of genes implicated in 
processes of cell cycle control, fibrosis and angiogenesis which are central to the PMF pathogenesis. 
Therefore, β-catenin may represent interesting new therapeutic target in these diseases. 
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Introduction: 
Primary myelofibrosis (PMF) is a Philadelphia chromosome negative myeloproliferative neoplasm 
(Ph- MPN)
1
 driven by clonal expansion of pluripotent hematopoietic stem cell.
2
 Proliferating clone 
and bone marrow stroma
3
 produce inflammatory cytokines leading to reactive bone marrow fibrosis, 
increased angiogenesis and subsequent development of extramedullary hematopoiesis. Although no 
disease-causing mutation has been recognized, JAK2, MPL or calreticulin mutations are present in 
majority of patients.
4
 Disease can manifest differently in individual patients with varying number of 
myeloid lineages proliferation or cytopenias, marked hepato and splenomegaly with associated 
complications and prominent constitutional symptoms.  
PMF related Ph- MPNs like polycythemia rubra vera (PRV) and essential thrombocytosis (ET) share 
common biological and clinical features with PMF and can evolve to secondary myelofibrosis (SMF) 
during course of disease. PMF and post PRV / post ET SMF have different molecular backgrounds; 
PMF harbors larger number of mutated genes while SMF more closely mirrors the disease of origin.
5, 6
 
Homeostasis of both healthy and diseased human tissues is regulated by a stem cell network of 
signaling cascades where canonical Wnt signaling cascade plays a pivotal role.
7
 Binding of canonical 
Wnt ligands (Wnt1, Wnt3a, Wnt8) with receptor Frizzled induces membranous complex formation 
with low-density-lipoprotein receptor related protein 5/6 (LRP5/6) and recruits intracellular proteins 
Dishevelled and Axin to plasma membrane.
8
 Without canonical Wnt stimulation, Axin resides in a 
complex with adenomatous polyposis coli (APC), glycogen synthase kinase 3 (GSK3) and casein 
kinase 1 (CK1). Complex captures central effector molecule of canonical Wnt signaling – β-catenin 
which leads to its phosphorylation, ubiquitination and subsequent degradation. Upon canonical Wnt 
stimulation, β-catenin is released from aforementioned protein complex, pairs with the lymphoid 
enhancer factor/T cell factor (LEF/TCF), enters nucleus and induces transcriptional activation of target 
genes involved in stem cell maintenance, expansion and lineage specification in both embryonic and 
adult tissues.
9
 Aberrant activation of canonical Wnt/β-catenin signaling increases propensity for cell 
malignant transformation and has been implicated in a wide array of malignant hematological 
disorders like multiple myeloma
10
, chronic lymphocytic leukemia
11
, chronic myelogenous leukemia 
(CML)
12
, acute myeloid leukaemia
13
 etc. There are few reports suggesting its dysregulation in Ph- 
MPNs
14, 15
 with PMF patients receiving only limited attention.  
Aim of this study was to analyze the expression of canonical Wnt effector β-catenin in bone marrow 
aspirates of patients with PMF and SMF through mRNA expression. We compared relative gene 
expression with clinical and hematological parameters. 
Patients and methods: 
Bone marrow aspirates of 29 patients with PMF and four patients with SMF who were diagnosed in 
our institution from 2004 to 2015 were analyzed. The diagnosis was established according to the 
current WHO / IWG-MRT criteria
16, 17
 and the degree of bone marrow fibrosis was graded according 
to the current European consensus.
18
 Control group consisted of 16 age and sex matched bone marrow 
aspirates obtained from patients with limited-stage aggressive Non-Hodgkin lymphoma without bone 
marrow involvement. All patients and controls provided written informed consent for bone marrow 
cryopreservation and molecular studies. The study was approved by the Institutional Review Board. 
Mononuclear cells were isolated from bone marrow aspirates using Histopaque (Sigma, St. Louis, 
MO, USA; density 1.077 g/mL) and preserved in liquid nitrogen using DMSO until needed. Total 
RNA was extracted using Trizol reagent (TriPure; Roche Mannheim, Germany), reversely transcribed 
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to cDNA (MuLV Reverse Transcriptase; Applied Biosystems, Foster City, CA) and amplified by 
quantitative PCR using CTNNB1 TaqMan gene expression assay (Hs00355049_m1 Thermo Fisher 
Scientific) in an ABI Prism 7300 Sequence Detection system (Applied Biosystems). QRT-PCR was 
performed in duplicate for each sample. Β-catenin relative expression was calculated as ΔCT values 
using abl as the reference gene (CTβ-catenin - CTabl). JAK2 V617F mutation analysis and transcript 
levels quantification were performed according to previously published methods.
19, 20
  
The normality of data distrubution was tested using the Shapiro-Wilk test. ΔCT values were compared 
using the Kruskal-Wallis one-way analysis of variance and corresponding post-hoc tests. Association 
between parameters was tested using the Spearman rank correlation or Mann Whitney U test where 
appropriate. All statistical tests were two-sided and P values <0.05 were considered significant. 
Analyses were performed using MedCalc Statistical Software version 16.2.0 (MedCalc Software bvba, 
Ostend, Belgium). 
Results: 
There were total of 49 patients and controls analyzed, 29 with PMF, four with SMF (three post PRV 
SMF, one post ET SMF) and 16 in control group. There were 31 (63%) male and 18 (37%) female 
patients, median age was 69 years. There were no significant differences in age or sex in target and 
control groups. Clinical characteristics of patients with PMF and SMF are shown in Table 1. 
Β-catenin relative expression differed significantly between groups (p=0.0002). Β-catenin was 
significantly higher expressed in both patients with PMF (median ΔCT -4.65) and SMF (median ΔCT -
4.27) than in control group (median ΔCT -3.39), but the expression did not differ significantly between 
PMF and SMF patients as shown in Figure 1.  
In patients with PMF, β-catenin relative expression correlated negatively with hemoglobin level 
(p=0,017), but no association according to age, sex, degree of bone marrow fibrosis, the spleen or the 
liver size, leukocyte or platelet counts, MCV, RDW, LDH, serum iron, TIBC, transferrin saturation, 
ferritin or CRP was detected. Also, no association between β-catenin relative expression and JAK2 
V617F mutational status was detected; JAK2 allele burden in mutated patients did not correlate with 
β-catenin expression (analyzed in 12 patients).  
Discussion: 
Present study shows for the first time that β-catenin mRNA expression is increased in patients with 
both primary and secondary (post Ph- MPN) myelofibrosis. We identified three previous studies 
investigating β-catenin expression in PMF with neither of them focusing primarily on this disease, 
SMF has not been investigated previously. First study was done by Serinsӧz et al13 who used qRT-PCR 
method to demonstrate increased β-catenin expression in PMF patients in comparison to CML but not 
in comparison to control group. It is to point out that mentioned study used RNA extracted from 
paraffin embedded bone marrow biopsies. Also, patients with reactive hyperplasia of 
megakaryopoiesis and/or erythropoiesis were used as control group. Second study was done by 
Jauregui et al
14
 who used immunohistochemistry to demonstrate lower expression of β-catenin in 
megakaryocytes of PMF and CML patients in comparison to PRV and ET. Third study was done by 
Geduk et al
15
 who used immunohistochemistry to analyze β-catenin expression in Ph- MPN subsets 
distinguishing expression in myeloid cells, megakaryocytes and vascular endothelial cells. They 
showed lower expression of β-catenin in megakaryocytes of PMF patients in comparison to ET and 
PRV (there was no difference between PMF and control group), no difference in β-catenin expression 
in myeloid cells among tested subsets and higher β-catenin expression in vascular endothelial cells of 
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PMF patients in comparison to PRV, ET and control group. Authors also reported positive correlation 
between β-catenin expression in megakaryocytes and hemoglobin level (for a whole Ph- MPN group 
represented with 43 ET, seven PRV and 16 PMF patients that differ in disease biology and hemoglobin 
levels) which is in contrast with our finding of negative correlation with hemoglobin level in pure 
PMF group. Our results suggest that upregulation of canonical Wnt/β-catenin signaling might 
potentiate anemia. This novel observation has clinical importance as lower hemoglobin levels bear 
adverse prognostic significance in PMF (but not other Ph- MPNs). In general, our findings are in 
support of previous observations that β-catenin may have important role in PMF. 
It was previously shown by Liu et al
21
 that JAK2 specific blockade can decrease β-catenin expression 
in human acute T cell leukemia Jurkat cells and in human erythroleukemia HEL cells. This effect can 
be attenuated by silencing beta-TrCP with specific shRNA, identifying beta-TrCP as cross-talk gene 
between JAK/STAT and Wnt/β-catenin signaling pathways. Expression of β-catenin in our study 
shows no association with either JAK2 V617F mutational status or JAK2 V617F allele burden which 
is in line with previous observations regarding Ph- MPNs
15, 22
 suggesting that β-catenin expression 
could independently contribute to pathogenesis of Ph- MPNs but future studies are needed.  
Canonical Wnt/β-catenin signaling is a part of larger stem cell signaling network where different 
cytokine signaling cascades cooperate or antagonize in a context dependent manner.
23
 The foundation 
of this network comprises of Wnt, FGF, Notch, TGFβ/BMP, and Hedgehog signaling cascades.24 
Elements of the network are mutually regulated and play a central role in stem cell fate determination 
by governing processes of self-renewal, proliferation and differentiation which are central to fetal and 
adult tissues homeostasis and carcinogenesis. Number of inflammatory cytokines associated with PMF 
are capable of mediating their effects through increased β-catenin expression (reported in different 
contexts), including TGFβ1,25, 26 FGF27 and PDGF.28, 29 Accordingly, β-catenin can induce expression 
of number of genes implicated in processes of cell cycle control (c-MYC, Cyclin D1),
30-32
 fibrosis 
(COL1, TGFβ, ET-1, CCN2)33, 34 and angiogenesis (IL-8, VEGF).35, 36 Which of aforementioned 
interactions are relevant in pathogenesis of PMF remains to be elucidated with further studies. Since 
clonal proliferation associated with bone marrow fibrosis and increased angiogenesis are central 
features of PMF and SMF, β-catenin may represent interesting new therapeutic target in these diseases.  
Conclusion: 
Both PMF and SMF patients have increased β-catenin expression in their bone marrows. Activation of 
canonical Wnt/β-catenin signaling might potentiate anemia in PMF and may contribute to malignant 
and fibrogenic potential of these diseases. This could provide interesting new therapeutic targets. 
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Clinical Practice Points:  
 Activation of Wnt/β-catenin signaling pathway promotes malignant transformation and 
development of fibrosis and angiogenesis.  
 Β-catenin contributes to pathogenesis of various hematological malignancies, including 
multiple myeloma and chronic myelogenous leukemia where its inhibition has been actively 
investigated. 
 The present study demonstrated increased β-catenin mRNA expression in bone marrows of 
patients with both primary (PMF) and secondary myelofibrosis (SMF) developing from 
previous Philadelphia chromosome negative myeloproliferative neoplasm. 
 Higher β-catenin expression is associated with lower hemoglobin level which bears negative 
prognostic significance in PMF. 
 Our results are providing additional evidence for role of β-catenin in pathogenesis of PMF and 
SMF which may help in recognizing new therapeutic targets in these diseases. 
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Table 1. Characteristics of patients with primary (PMF) and secondary myelofibrosis (SMF). Values 
are presented as proportions or as median and range. 
 PMF SMF 
Total number 29 4 
Sex 
19 / 29 (66%) males 
10 / 29 (34%) females 
2 / 4 (50%) males 
2 / 4 (50%) females 
Age 70 (55 – 81) years 71 (57 – 79) years 
JAK2 V617F positive 19 / 29 (66%) 2 / 4 (50%) 
Hemoglobin level (g/L) 101 (75 – 162) 102 (96 – 135) 
WBC (x10^9/L) 10.9 (2.1 – 150.6) 13.1 (6.9 – 22.0) 
Platelet count (x10^9/L) 366 (22 - 1491) 438 (276 - 727) 
MCV (fL) 86.75 (69.9 – 113.9) 87.5 (69.1 – 118.9) 
RDW (%) 19.55 (15.0 - 29.2) 20.1 (18.3 – 25.4) 
LDH (U/L) 538.5 (152 – 3400) 795.5 (352 – 1151) 
CRP (mg/L) 5.9 (0.5 – 245.0) 8.7 (0.3 – 159.5) 
Ferritin (mcg/L) 152 (10 – 10720) 148.5 (16 – 1427) 
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Figure 1. Β-catenin mRNA expression is significantly increased in patients with primary and 
secondary mylofibrosis in comparison with control group (Kruskal-Wallis one-way analysis of 
variance, p=0.0002). Relative expression is shown as ΔCT values using abl as the reference gene. ΔCT 
values are plotted in reverse order for the results to be easier to view and interpret (higher expression 
is positioned higher in diagram). PMF: primary myelofibrosis, SMF: secondary myelofibrosis; Cont.: 
control group; n.s.: non significant.  
 
